JMM Pharma Solutions Spółka z Ograniczoną Odpowiedzialnością (KRS 0000453079, NIP 7010371397) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. JMM PHARMA SOLUTIONS operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since March 1, 2013. JMM PHARMA SOLUTIONS's most recently reported net revenue was 2.0 M PLN for 2018.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - JMM Pharma Solutions
Identity
- Name
- JMM Pharma Solutions Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- March 1, 2013
- Registry status as of
- November 21, 2025
- Latest entry
- May 21, 2021
- Founding act
- 14.02.2013R., NOTARIUSZ TOMASZ WOJCIECHOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 1161/2013.
Articles of association history (2)
- February 14, 2013: 14.02.2013R., NOTARIUSZ TOMASZ WOJCIECHOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 1161/2013.
- November 24, 2015: 24.11.2015, REP. A NR 4727/2015, NOTARIUSZ TOMASZ WOJCIECHOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE PRZY UL. KOSZYKOWEJ 60/62. ZMIANA: §1 UMOWY.
Activities
Main activity
47.73.ZDispensing chemist in specialised stores
Other activities
Address and contact
- Address
- UL. FRANCISZKA MARII LANCIEGO, 16, 191, 02-792, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- BIURO@JMMPHS.COM
- Website
- WWW.JMMPHS.COM
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - JMM Pharma Solutions
Credibility rating
39.1 / 100
Poor credibility
Insolvency risk
Low
Elevated threat
Closure risk
18
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/13 yrs
Board changes
3
3/13 yrs
PKD changes
1
1/13 yrs
Name changes
1
1/13 yrs
Data from 13 years of registry activity.
Operational status - JMM Pharma Solutions
Founded
March 1, 2013
13 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
50.0 K PLN
500 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
1 year
2018
Registry entries
18
latest: May 21, 2021
Revenue
2.0 M PLN
2018
Net profit
774.07 PLN
2018
Assets
741.8 K PLN
2018
Equity
114.0 K PLN
2018
EBITDA
117.4 K PLN
2018
Valuation
57.0 K PLN
Medium confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - JMM Pharma Solutions.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
